Assessing AbbVie (ABBV) Valuation After New Dermatology Data Underpins Immunology Growth Potential

Simply Wall St.03-30

AdvertisementAbbVie’s dermatology data and why it matters for the stock AbbVie (ABBV) just put a spotlight on its dermatology franchise at the 2026 American Academy of Dermatology meeting, sharing 24 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623392373?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285","is_english":true,"pubTime":"2026-03-30 14:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623392373","market":"sg","top_or_hot":-1,"title":"Assessing AbbVie (ABBV) Valuation After New Dermatology Data Underpins Immunology Growth Potential","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementAbbVie’s dermatology data and why it matters for the stock AbbVie (ABBV) just put a spotlight on its dermatology franchise at the 2026 American Academy of Dermatology meeting, sharing 24 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/assessing-abbvie-abbv-valuation-after-new-dermatology-data-u\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing AbbVie (ABBV) Valuation After New Dermatology Data Underpins Immunology Growth Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing AbbVie (ABBV) Valuation After New Dermatology Data Underpins Immunology Growth Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-30 14:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/assessing-abbvie-abbv-valuation-after-new-dermatology-data-u><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementAbbVie’s dermatology data and why it matters for the stock AbbVie (ABBV) just put a spotlight on its dermatology franchise at the 2026 American Academy of Dermatology meeting, sharing 24 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/assessing-abbvie-abbv-valuation-after-new-dermatology-data-u\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0661504455.SGD","symbol_name":"Blackrock Global Equity Income A5 SGD-H","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/assessing-abbvie-abbv-valuation-after-new-dermatology-data-u","article_id":"2623392373","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/assessing-abbvie-abbv-valuation-after-new-dermatology-data-u","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2623392373","pubTimestamp":1774850928,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"AbbVie’s dermatology data and why it matters for the stock\nAbbVie (ABBV) just put a spotlight on its dermatology franchise at the 2026 American Academy of Dermatology meeting, sharing 24 abstracts across psoriasis, atopic dermatitis, vitiligo and alopecia areata, including late-stage and long-term safety data.\nSee our latest analysis for AbbVie.\nDespite the strong dermatology update, recent partnerships, and governance debates, AbbVie’s share price has slipped in recent months. Its year to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4581":"高盛持仓","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4139":"生物科技","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","ABBV":"艾伯维公司","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC"},"translate_title":"在新的皮肤病学数据支撑免疫学增长潜力后评估艾伯维(ABBV)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1.5},"content_text":"AdvertisementAbbVie’s dermatology data and why it matters for the stock AbbVie (ABBV) just put a spotlight on its dermatology franchise at the 2026 American Academy of Dermatology meeting, sharing 24 abstracts across psoriasis, atopic dermatitis, vitiligo and alopecia areata, including late-stage and long-term safety data. See our latest analysis for AbbVie. Despite the strong dermatology update, recent partnerships, and governance debates, AbbVie’s share price has slipped in recent months. Its year to date share price return of 8.68% contrasts with a 5 year total shareholder return of 138.89%, suggesting longer term momentum remains stronger than the shorter term picture. If you like the healthcare angle behind AbbVie’s dermatology work, it could be worth seeing what else is developing across 33 healthcare AI stocks. With AbbVie shares showing a modest 1-year total return of 3.30% compared with a much stronger 5-year total return of 138.89%, plus an indicated 18.98% gap to analyst targets and a 43.61% intrinsic discount, is this a genuine opportunity or is the market already baking in tomorrow’s growth? Most Popular Narrative: 17.3% Undervalued Vestra’s widely followed narrative pegs AbbVie’s fair value at $253.23 per share, compared with the latest close of $209.40. This frames the current pullback as a valuation gap rather than a trend break.  The fair value for AbbVie (ABBV) is calculated using my fair value method by applying a 17.5x Forward P/E multiple to my 2026 midpoint guidance of $14.47 EPS, reflecting my successfully navigated patent cliff and high-single-digit growth profile. This results in a fair value of $253.23 USD in local currency. At the current price of $219.68, the stock is trading at a 13.2% discount to its intrinsic value. I arrived at this fair value by balancing the 20% immunology growth and 3.1% dividend yield against the Imbruvica declines and broader drug-pricing legislative risks; this calculation confirms that ABBV remains a \"Core Value\" holding where the market is still slightly underestimating the scale of the Skyrizi/Rinvoq era.  Read the complete narrative. Curious what sits behind that fair value, beyond headline revenues and EPS guidance? The narrative leans on a specific growth mix, margin profile, and cash flow deployment that hold together only if a few key assumptions line up just right. Result: Fair Value of $253.23 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on immunology growth staying on track, and drug pricing or reimbursement changes not hitting key products harder than the market currently expects. Find out about the key risks to this AbbVie narrative. Another Way To Look At AbbVie’s Value Vestra’s fair value relies on a P/E based approach, but Simply Wall St’s DCF model comes out even more optimistic, with an estimate of future cash flow value at $371.32 per share versus the current $209.40. If the cash flow view is closer to reality, how comfortable are you with that gap? Look into how the SWS DCF model arrives at its fair value. ABBV Discounted Cash Flow as at Mar 2026Next Steps With mixed signals on value and sentiment, it helps to see the full picture yourself. Check the balance of 2 key rewards and 5 important warning signs. Looking for more investment ideas? If you stop at AbbVie, you could miss other opportunities that match your style, so use the screener to line up your next round of ideas.  Target reliable cash generators by scanning companies with robust finances using the solid balance sheet and fundamentals stocks screener (39 results). Spot potential mispricing by zeroing in on companies flagged as 62 high quality undervalued stocks. Broaden your watchlist with quality names uncovered through a screener containing 25 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623392373","isCrawlerRequest":true}